The Central Regenerative Medicine Project

TOP > Business > The Central Regenerative Medicine Project

This project will, based on the same technology as The Local Hospital Regenerative Medicine project, create few centers that conduct cell cultures, and provide the finished products or medical instrument products to the hospitals. By doing so, medical institutions can introduce regenerative medicine without establishing a cell culture facility, which will promote regenerative medicine. This may reduce the cost per patient while increasing the number of patients and hospitals that benefit from this practice by about 1,000 times.

Business model for medical products to regenerate cartilages using MSCs

Features of “medical products to regenerate cartilage using MSCs” under development
1.Processing to TEC

TEC is a new tissue engineering technique for cartilage repair using a scaffold-free tissue engineered construct bio-synthesized from synovium-derived MSCs. It was invented by Prof. Norimasa Nakamura, invited Professor at the Center for Advanced Medical Engineering and Informatics, Osaka University and Professor at the Osaka Health Science University, and Prof. Hideki Yoshikawa from the Department of Orthopaedics Osaka University Graduate School of Medicine.


2.Culture synovial-derived MSCs in a serum free culture medium

We use “technology to culture MSCs in a serum-free culture medium” co-developed by TWOCELLS and Dr. Yukio Kato (Officer at TWOCELLS), Professor, Division of Molecular Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University.
Previous studies demonstrated that synovial-derived MSCs proliferate more quickly than those derived from bone marrow or adipose.

3.Use cells derived from the same species (allogeneic)

A large amount of products for 1,000–10,000 people can be manufactured from a fraction of synovial tissue, and procedures, including cell adjustment, are not required in medical institutions, which will enable treatment of many patients.

4.Damaged cartilage and osteoarthritis as target diseases

According to the University of Tokyo Hospital, the estimated number of Japanese (aged 50 years or more) with knee joint disease is 30.8 million (54% of men and 75% of women), and about 10 million of them are said to require treatment. As a result of the National Livelihood Survey conducted by the Ministry of Health, Labor, and Welfare, a joint disease is the fourth most common reason why elders start to receive nursing, while falling and fractures are the fifth most common one. It is strongly desired to develop a safe and economical treatment for knee joint diseases in order to maintain/improve the quality of life (QOL) of elders, extend their healthy lifespan, and reduce medical cost.

©TWOCELLS Company Limited All Rights Reserved.